The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Occurrence and Frequency of Arrhythmias in Hypertrophic Cardiomyopathy in Relation to Delayed Enhancement on Cardiovascular Magnetic Resonance
Open accessAbstract
Objectives Our aim was to determine whether myocardial fibrosis, detected by cardiovascular magnetic resonance (CMR), represents an arrhythmogenic substrate in hypertrophic cardiomyopathy (HCM).Background Myocardial fibrosis is identified frequently in HCM; however, the clinical significance of this finding is uncertain.Methods We studied prevalence and frequency of tachyarrhythmias on 24-h ambulatory Holter electrocardiogram (ECG) with regard to delayed enhancement (DE) on contrast-enhanced CMR in 177 HCM patients (age 41 +/- 16 yrs; 95% asymptomatic or mildly symptomatic).Results Premature ventricular contractions (PVCs), couplets, and nonsustained ventricular tachycardia (NSVT) were more common in patients with DE than those without DE (PVCs: 89% vs. 72%; couplets: 40% vs. 17%; NSVT: 28% vs. 4%; p < 0.0001 to 0.007). Patients with DE also had greater numbers of PVCs (202 +/- 655 vs. 116 +/- 435), couplets (1.9 +/- 5 vs. 1.2 +/- 10), and NSVT runs (0.4 +/- 0.8 vs. 0.06 +/- 0.4) than non-DE patients (all p < 0.0001); DE was an independent predictor of NSVT (relative risk 7.3, 95% confidence interval 2.6 to 20.4; p < 0.0001). However, extent (%) of DE was similar in patients with and without PVCs (8.2% vs. 9.1%; p = 0.93), couplets (8.5% vs. 8.4%; p = 0.99), or NSVT (8.3% vs. 8.5%; p = 0.35).Conclusions In this large HCM cohort with no or only mild symptoms, myocardial fibrosis detected by CMR was associated with greater likelihood and increased frequency of ventricular tachyarrhythmias (including NSVT) on ambulatory Holter ECG. Therefore, contrast-enhanced CMR identifies HCM patients with increased susceptibility to ventricular tachyarrhythmias.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The frequency is related to the degree of myocardial fibrosis”
From 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry (2017) · cites this paper as Adabag et al., 2008
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kim, R. J., Wu, E., Rafael, A., Chen, E.-L., Parker, M. A., Simonetti, O. P., Klocke, F. J., Bonow, R. O., & Judd, R. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432003 · Cited by 3,308
Kim, R. J., Fieno, D. S., Parrish, T. B., Harris, K. R., Chen, E.-L., Simonetti, O. P., Bundy, J. M., Finn, J. P., Klocke, F. J., & Judd, R. M. (1999) · Circulation · doi:10.1161/01.cir.100.19.1992 · Cited by 2,583
Sudden Death in Young Competitive Athletes: Clinical, Demographic, and Pathological Profiles
Maron, B. J. (1996) · JAMA · doi:10.1001/jama.1996.03540030033028 · Cited by 1,693
Self-citationMaron, B. J., McKenna, W. J., Danielson, G. K., KAPPENBERGER, L. J., Kuhn, H. J., Seidman, C. E., Shah, P. M., Spencer, W. H., Spirito, P., ten Cate, F. J., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00941-0 · Cited by 1,572
Self-citationSudden Death in Young Athletes
Maron, B. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022783 · Cited by 1,394
Self-citationGrothues, F., Smith, G. C., Moon, J. C. C., Bellenger, N. G., Collins, P., Klein, H. U., & Pennell, D. J. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02381-0 · Cited by 1,267
Cardiovascular Magnetic Resonance, Fibrosis, and Prognosis in Dilated Cardiomyopathy
Assomull, R. G., Prasad, S. K., Lyne, J. C., Smith, G., Burman, E., KHAN, M. G., Sheppard, M. N., Poole-Wilson, P. A., & Pennell, D. J. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.049 · Cited by 1,163
Sudden death in hypertrophic cardiomyopathy: identification of high risk patients
Elliot, P. M., Poloniecki, J. D., Dickie, S., Sharma, S., Monserrat, L., Varnava, A. M., Mahon, N., & McKenna, W. J. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)01003-2 · Cited by 976
Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies
Mahrholdt, H., Wagner, A., Judd, R. M., Sechtem, U. P., & Kim, R. J. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi258 · Cited by 914
Maron, B. J., Shen, W.-K., Link, M. S., Epstein, A. E., Almquist, A. K., Daubert, J. P., Bardy, G. H., Favale, S., Rea, R. F., Boriani, G., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420601 · Cited by 832
Self-citation
Cited by
Sorted by citations
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
Authors/Task Force members, Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu284 · Cited by 4,332
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318223e2bd · Cited by 2,116
Self-citation2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.011 · Cited by 1,276
Self-citationMaron, B. J., & Maron, M. S. (2013) · The Lancet · doi:10.1016/s0140-6736(12)60397-3 · Cited by 1,231
Self-citationPrognostic Significance of Myocardial Fibrosis in Hypertrophic Cardiomyopathy
O’Hanlon, R., Grasso, A. E., Roughton, M., Moon, J., Clark, S., Wage, R., Webb, J., Kulkarni, M., Dawson, D. K., Sulaibeekh, L., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.010 · Cited by 816
Metadata
- Authors
- Adabag, A. S., Maron, B. J., Appelbaum, E., Harrigan, C. J., Buros, J. L., Gibson, C. M., Lesser, J. R., Hanna, C. A., Udelson, J. E., Manning, W. J., & Maron, M. S.
- Affiliations
- Minneapolis Heart Institute Foundation (US)
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Tufts Medical Center (US)
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2008-04
- Volume
- 51
- Issue
- 14
- Pages
- 1369-1374
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2076526672
- Cited by
- 662
- References
- 43
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 12 · 2023: 14 · 2022: 15 · 2021: 24 · 2020: 24 · 2019: 28 · 2018: 32 · 2017: 29 · 2016: 39 · 2015: 42 · 2014: 64 · 2013: 48 · 2012: 60
- FWCI
- 50.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Clinical Science Research and Development
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Effects of Exercise
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- hypertrophic cardiomyopathy, myocardial fibrosis, late gadolinium enhancement, cardiovascular magnetic resonance, ventricular arrhythmias, non-sustained ventricular tachycardia, premature ventricular contractions, arrhythmogenic substrate, Holter monitoring, asymptomatic patients, arrhythmic risk stratification, contrast-enhanced MRI, cardiac resynchronization therapy, implantable cardioverter-defibrillator
- MeSH terms
- Adolescent, Adult, Aged, Cardiomyopathy, Hypertrophic, Female, Fibrosis, Health Status Indicators, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Prospective Studies, Tachycardia, Time Factors, Prevalence, Risk Assessment, Blood Pressure Monitoring, Ambulatory, Ventricular Premature Complexes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
